Fig. 4From: Avelumab in patients with previously treated metastatic melanoma: phase 1b results from the JAVELIN Solid Tumor trialBest change in sum of target lesion diameters from baseline (a), and PFS (b) and OS (c) according to tumor PD-L1 expression status at 1% cutoff in evaluable patientsBack to article page